Phase I study of CC-90010, a reversible, oral BET inhibitor...

  • Main
  • 2020 / 3
  • Phase I study of CC-90010, a reversible, oral BET inhibitor...
Annals of Oncology 2020 / 3

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Moreno, V., Sepulveda, J.M., Vieito, M., Hernández-Guerrero, T., Doger, B., Saavedra, O., Ferrero, O., Sarmiento, R., Arias, M., De Alvaro, J., Di Martino, J., Zuraek, M., Sanchez-Pérez, T., Aronchi
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.03.294
Date:
March, 2020
File:
PDF, 4.80 MB
2020
Conversion to is in progress
Conversion to is failed